FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and namely to immunology. It can be used to make vaccines on the basis of a nucleic acid. The vaccine contains one or more mRNA polynucleotides having an open reading frame encoding an antigenic polypeptide, and the antigenic polypeptide is derived from a bacterial agent or a viral agent forming a cationic lipid nanoparticle that contains 40-60% of ionizable cationic lipids, 5-15% of neutral lipids, 25-40% of sterol and 0.5-15% of PEG-modified lipids. The group of inventions also relates to a vaccine containing one or more mRNA polynucleotides having an open reading frame encoding a hemagglutinin protein, and a pharmaceutically acceptable carrier or an excipient forming a cationic lipid nanoparticle containing 40-60% of ionizable cationic lipids, 5-15% of neutral lipids, 25-40% of sterol and 0.5-3% of PEG-modified lipids. The mRNA polynucleotide includes a chemical modification. The chemical modification includes N1-methylpsevdouridine or 5-methylcytosine.
EFFECT: use of these lipid carriers in certain ratios makes it possible to efficiently deliver mRNA to a subject in vivo.
69 cl, 28 ex, 49 tbl, 23 dwg
